SAT-455 Analysis of a Group of Prolactinomas Resistant to Treatment with Dopamine Agonists at a University Hospital in Buenos Aires, Argentina

Prolactinomas represent approximately 40-60% of all pituitary tumors. Dopamine agonists (DA) are the first-line treatment, with a 70-90% response. However, up to 10% are resistant (R) to DA. Our objectives were to describe the clinical, biochemical and imaging characteristics of a group of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez Pernas, Mariana, Sosa, Soledad, Manavela, Marcos, Gonzalez Abbati, Santiago, Bruno, Oscar, Danilowicz, Karina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552054/
http://dx.doi.org/10.1210/js.2019-SAT-455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552054/
http://dx.doi.org/10.1210/js.2019-SAT-455

Ejemplares similares